This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Ziprasidone in Children With Autism: A Pilot Study

This study has been completed.
Information provided by:
Drexel University Identifier:
First received: September 13, 2005
Last updated: June 15, 2010
Last verified: June 2010
The purpose of this study is to see if the drug, ziprasidone, is effective in treating problems in adolescent associated with autism.

Condition Intervention Phase
Autism Drug: Ziprasidone Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ziprasidone in Children With Autism: A Pilot Study

Resource links provided by NLM:

Further study details as provided by Drexel University:

Primary Outcome Measures:
  • Clinical Global Impressions [ Time Frame: Week 6 ]

Secondary Outcome Measures:
  • Children's Psychiatric Rating Scale [ Time Frame: Baseline, Week 6 ]

Enrollment: 15
Study Start Date: February 2002
Study Completion Date: August 2006
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 Open Label
Open Label
Drug: Ziprasidone
Ziprasidone 40mg to 60mg per day, individually titrated
Other Name: Geodon

  Show Detailed Description


Ages Eligible for Study:   12 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of autism (DSM-IV) made by a boarded child and adolescent psychiatrist.
  • Males and females.
  • Aged 12 to 18 years.
  • Clinical judgment that medication treatment for autism is indicated.

Exclusion Criteria:

  • Major medical problems including cardiac, liver, endocrine, or renal diseases.
  • History of seizure disorder or gross neurological deficit.
  • Baseline QTC greater than 425 msec.
  • Concomitant treatment with psychotropic medication.
  • History of prior exposure to ziprasidone.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00208559

United States, Pennsylvania
Drexel University College of Medicine at Friends Hospital
Philadelphia, Pennsylvania, United States, 19124
Sponsors and Collaborators
Drexel University College of Medicine
Principal Investigator: Richard P Malone, MD Drexel University College of Medicine
  More Information

Responsible Party: Richard P. Malone, Drexel University College of Medicine Identifier: NCT00208559     History of Changes
Other Study ID Numbers: 00936
Study First Received: September 13, 2005
Last Updated: June 15, 2010

Keywords provided by Drexel University:
Pervasive Developmental Disorder

Additional relevant MeSH terms:
Autistic Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents processed this record on August 18, 2017